Shelton Capital Management Reduces Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Shelton Capital Management trimmed its position in shares of Penumbra, Inc. (NYSE:PEN) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,463 shares of the company’s stock after selling 58 shares during the period. Shelton Capital Management’s holdings in Penumbra were worth $347,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. UMB Bank n.a. grew its stake in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after acquiring an additional 70 shares during the period. Hurley Capital LLC purchased a new stake in Penumbra during the fourth quarter valued at about $56,000. Huntington National Bank boosted its position in Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after purchasing an additional 154 shares during the period. Mather Group LLC. increased its stake in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after purchasing an additional 208 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its position in shares of Penumbra by 25.0% in the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after purchasing an additional 75 shares during the period. 88.88% of the stock is currently owned by institutional investors.

Penumbra Stock Performance

NYSE PEN opened at $268.74 on Friday. The company has a market capitalization of $10.35 billion, a P/E ratio of 790.42, a P/E/G ratio of 2.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a fifty day moving average of $274.12 and a 200-day moving average of $248.20.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares of the company’s stock, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the completion of the transaction, the chief financial officer now owns 15,243 shares in the company, valued at approximately $4,359,498. The trade was a 11.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,236 shares of company stock valued at $31,222,390 over the last quarter. 5.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $330.00 price objective (up from $250.00) on shares of Penumbra in a report on Wednesday, February 19th. Royal Bank of Canada raised their price target on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their price objective on Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Wells Fargo & Company raised their target price on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Robert W. Baird upped their price target on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Penumbra has a consensus rating of “Moderate Buy” and an average target price of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.